Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Playing Doctor: The Impact of the Tysabri Risk Plan

This article was originally published in RPM Report

Executive Summary

The market resurrection of Tysabri demonstrates the power of risk management but raises a tough question: how far can FDA and industry go into the practice of medicine? Biogen Idec declare they are nt trying to tell doctors how to practice. The strict rules of the risk management plan suggest otherwise.

You may also be interested in...



Waking Up to REMS (Part 3): Redefining Marketing

FDA's new post-marketing safety authorities place unprecedented burdens on pharmaceutical marketers. But they do something else: redefine a favorite target of industry critics as a regulatory requirement rather than a suspicious activity.

Waking Up to REMS (Part 3): Redefining Marketing

FDA's new post-marketing safety authorities place unprecedented burdens on pharmaceutical marketers. But they do something else: redefine a favorite target of industry critics as a regulatory requirement rather than a suspicious activity.

Celgene's Revlimid Serves as Precedent for Tysabri Delay Concerns

FDA says it needs more time to review an application for the MS drug Tysabri for treatment of Crohn's Disease. Investors worry the delay may be a red flag of safety issues related to the new indication. Recent history with more complex risk plans indicates Wall Street may be getting worked up over nothing.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel